Loncastuximab Tesirine (Genetical Recombination)



Loncastuximab Tesirin is an antibody-drug-conjugate (molecular weight: ca. 151,000) consisting of Tesirine ((3RS)-1-[(2S,5S)-1-{[4-({[(11S,11aS)-11-hydroxy-7-methoxy-8-[(5-{[(11aS)-7-methoxy-2-methyl-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl]oxy}pentyl)oxy]-2-methyl-5-oxo-5,10,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-carbonyl]oxy}methyl)phenyl]amino}-5-(1-methylethyl)-2-methyl-1,4,7,35-tetraoxo-10,13,16,19,22,25,28,31-octaoxa-3,6,34-triazaheptatriacontan-37-yl]-2,5-dioxopyrrolidin-3-yl group (C₇₅H₁₀₂N₉O₂₃; molecular weight: 1,497.66)), which is composed of pyrrolobenzodiazepine dimer and linker, attached to an average of 2-3 cysteine residues of the recombinant monoclonal antibody. The antibody moiety is a recombinant anti-CD19 monoclonal antibody whose variable regions are derived from mouse antibody and other regions are derived from human IgG1, and the C-terminal K450 is deleted in the H-chain. The antibody is produced in CHO cells. The protein moiety is a glycoprotein (molecular weight: ca. 147,000) composed of 2 H-chains (γ1-chains) consisting of 449 amino acid residues each and 2 L-chains (κ-chains) consisting of 211 amino acid residues each.

[1879918-31-6]